Patents Assigned to Otsuka Pharmaceutical Co., Ltd.
  • Publication number: 20210361616
    Abstract: An ameliorating agent for a female-specific physical and/or mental unpleasant symptom, which contains ?-tocopherol and/or equol. A method of ameliorating a female-specific physical and/or mental unpleasant symptom, the method including administering ?-tocopherol and equol, wherein 0.1 to 1000 mg per day of ?-tocopherol and 0.1 to 50 mg per day of equol are administered.
    Type: Application
    Filed: August 9, 2021
    Publication date: November 25, 2021
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tomomi UENO, Tomoko Deguchi, Atsuko Onoda
  • Publication number: 20210361615
    Abstract: An ameliorating agent for a female-specific physical and/or mental unpleasant symptom, which contains ?-tocopherol and/or equol. A method of ameliorating a female-specific physical and/or mental unpleasant symptom, the method including administering ?-tocopherol and equol, wherein 0.1 to 1000 mg per day of ?-tocopherol and 0.1 to 50 mg per day of equol are administered.
    Type: Application
    Filed: August 9, 2021
    Publication date: November 25, 2021
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tomomi UENO, Tomoko DEGUCHI, Atsuko ONODA
  • Patent number: 11173290
    Abstract: The present invention discloses multiple approaches to preventing the capsule walls and other material from interfering with the performance of an electronic device once the device is activated by surrounding fluid. In accordance with the teachings of the present invention, a miniature ingestible device (MID) may be created using excipients and films. The MID, in accordance with various aspects of the present invention, will have a coating or laminating surrounding an electronic device and separating and isolating the device from the pharmaceutical product or drug within the capsule once the capsule is ingested as well as from the capsule itself as the capsule walls begin to collapse during the disintegration process.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: November 16, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Timothy Robertson, Hooman Hafezi, Raymond Schmidt
  • Patent number: 11166939
    Abstract: Provided herein are compositions for the ingestible administration of lisinopril. In some embodiments the compositions comprise lisinopril and silicon. In some embodiments, the compositions comprise lisinopril, silicon, magnesium metal, and copper (I) chloride. Also provided herein are apparatuses comprising the compositions provided herein. Also provided herein are methods for using the compositions and apparatuses provided herein.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: November 9, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO. LTD
    Inventors: Kurt Scheinpflug, Nikhil Pargaonkar, Chris Dong, Ai Ling Ching, Dawn Adkin
  • Publication number: 20210338166
    Abstract: Improved ingestible event markers are provided. Aspects of the markers may include the presence of a matrix layer that includes a binder and source of an electron acceptor. Alternatively or in addition to the matrix layer, aspects of the markers may include a large surface area electrode having a surface area that exceeds the surface area of the circuitry of the marker. Aspects further include methods of making and using the ingestible event markers.
    Type: Application
    Filed: May 21, 2021
    Publication date: November 4, 2021
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Patricia Johnson, Raymond Schmidt, Anuj Patel, Kevin Cheng, Kosuke Iwai, Hooman Hafezi
  • Publication number: 20210340157
    Abstract: Provided is a novel heterocyclic compound having an aryl hydrocarbon receptor antagonist activity and useful for the promotion of platelet production, the compound being represented by the general formula [I]: wherein ring A, ring B, R1, R2, R3, R4, n, and X are as defined above, or a salt thereof.
    Type: Application
    Filed: September 6, 2019
    Publication date: November 4, 2021
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhiro OHDACHI, Yusuke FUJIMORI, Naoya MAKITA, Noritaka KOSEKI, Hideki HAYASHI, Yuki SAKAMOTO, Kurumi MINENO, Ryosuke TAGA
  • Publication number: 20210330216
    Abstract: A system, a wearable device, and a method are provided which can increase the accuracy of physiological metrics while detecting if the patient ingested digital medicine and/or improve performance of the wearable device. The wearable device can comprise machine executable instructions that when executed by the processor, cause the processor to perform various algorithms, such as, for example, at least one of a step count algorithm, a body angle algorithm, a heart rate algorithm, a peak finder algorithm, an adaptive thresholding algorithm, a heart rate variability algorithm, a R-R cleaning Algorithm, a deltaR-R cleaning algorithm, a merge twin interval algorithm, a split tall intervals algorithm, an absorb short intervals algorithm, a bimodal detection algorithm, and a resting algorithm.
    Type: Application
    Filed: June 14, 2019
    Publication date: October 28, 2021
    Applicant: OTSUKA PHARMACEUTICAL CO. LTD.
    Inventors: Robert AZEVEDO, Neraj P. BOBRA, Aditya DUA, Ronny X. LI, William A. WEEKS
  • Patent number: 11154553
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: October 26, 2021
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Arash Raoufinia
  • Patent number: 11158149
    Abstract: A target authentication device includes an electrode to detect an electrical signal associated with a user of the device. The electrical signal represents an authentication code for the device. An authentication receiver module is coupled to the electrode. The module receives the electrical signal from the electrode and determines whether the electrical signal matches a predetermined criterion to authenticate the identity of the user based on the electrical signal. An authentication module is also disclosed. The authentication module includes one electrode to couple an electrical signal associated with a user to a user of a target authentication device, the electrical signal represents an authentication code for the device. An authentication transmission module is coupled to the electrode. The authentication transmission module transmits the electrical signal from the electrode. A method of authenticating the identity of a user of a target authentication device also is disclosed.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: October 26, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Timothy Robertson, George Savage, Benedict Costello, David O'Reilly
  • Patent number: 11154507
    Abstract: An object of the present invention is to provide a freeze-dried aripiprazole powder formulation that exhibits good dispersibility and is easily dispersed into a homogenous suspension when reconstituted with water. The present invention provides a freeze-dried aripiprazole formulation obtained by a process comprising the steps of spraying for freezing an aripiprazole suspension containing (I) aripiprazole, (II) a vehicle for the aripiprazole, and (III) water for injection, and drying.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: October 26, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Shogo Hiraoka
  • Patent number: 11147821
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: October 19, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
  • Patent number: 11149123
    Abstract: Highly-swellable polymeric films are provided. Aspects also include ingestible compositions that include the highly-swellable polymeric film and an ingestible component. Aspects further include methods of making and using the compositions.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: October 19, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hooman Hafezi, Raymond Schmidt
  • Patent number: 11142518
    Abstract: This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide, and in particular to novel physical forms of the compound, a process for preparing the compound and synthetic intermediates for use in the process, and novel formulations containing the compound, as well as therapeutic uses of the compound.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: October 12, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Michael Reader, Nicola Elizabeth Wilsher, Mark Henry Saunders, Paul Anthony Baguley, Colin Thomas Lindley, Robert Craig Melling, Bozena Ewa Adamczyk, Mirka Scarati
  • Patent number: 11104650
    Abstract: An improved process for preparing 2-chloro-4-nitroimidazole derivatives which are useful intermediates in the preparation of an anti-tuberculosis drug is provided. The process may comprise the step of chlorinating nitroimidazoles with a chlorinating agent and an activating agent to give 2-chloro-4-nitroimidazole derivatives.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: August 31, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Petr Novak, Petr Zahradnik, Jiri Tauchman, Jan Koci, Antonin Sturc
  • Patent number: 11102038
    Abstract: A method may comprise receiving and sampling a signal. The signal may encode a data packet. A slice may be generated and stored comprising a pair of values for each of a selected number of samples of the signal representing a correlation of the signal to reference functions in the receiver. The presence of the data packet may then be detected and the detected packet decoded from the stored slices. The generating and storing slices may be carried out as the received signal is sampled. The sampled values of the signal may be discarded as the slices are generated and stored. The slice representation of the signal can be manipulated to generate filters with flexible bandwidth and center frequency.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: August 24, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Robert Fleming, Cherie Kushner, William H. McAllister, Mark Zdeblick
  • Patent number: 11097007
    Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: August 24, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Daiki Kaneko, Takakuni Matsuda, Yusuke Hoshika
  • Patent number: 11098067
    Abstract: The present invention relates to a method of production of 4-boronophenylalanine (BPA) from 4-iodophenylalanine, in which all the functional groups of the amino acid are protected by benzyl protection method, and which uses isopropyl magnesium halogenide stabilized by a complexation base, and subsequent condensation of the resulting Grignard reagent with a boric acid ester. The final reaction step, catalytic hydrogenolysis or transfer hydrogenolysis of protecting groups on the amino acid, occurs after hydrolysis of the boronate ester groups.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: August 24, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Petr Zahradnik, Antonin Sturc, Jiri Malinak, Jan Koci
  • Publication number: 20210251902
    Abstract: Provided is a composition comprising delamanid particles for which the formation of secondary particles is suppressed. Specifically, provided is a composition comprising (A) delamanid particles and (B) a surface stabilizer.
    Type: Application
    Filed: June 11, 2019
    Publication date: August 19, 2021
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Atsuya NAKAMURA, Hiroyuki YAMAZAKI, Masahiro HASEGAWA, Naoki KAMADA
  • Publication number: 20210228540
    Abstract: The present application provides a method for improvement in physical activity efficiency, a method for reducing fatigue, and a method for improving dynamic/kinetic visual acuity, comprising administering a composition comprising a kaempferol analog to a subject in need thereof.
    Type: Application
    Filed: April 12, 2021
    Publication date: July 29, 2021
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Yasutaka IKEDA, Tsubasa MIZOKAMI, Yasuhiro ABIRU, Minoru AKIYAMA, Ayuko OYAMA
  • Patent number: 11051543
    Abstract: An ingestible compositions includes a first polymer layer, an adhesive layer associated with the first polymer layer, where the adhesive layer includes an adhesive material and is configured to releasably adhere to the first polymer layer, an alginate layer adhered to the adhesive layer, and a second polymer layer associated with the alginate layer and configured to releasably adhere to the alginate layer. Aspects further include methods of making and using the compositions.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: July 6, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO. LTD.
    Inventors: Raymond Schmidt, Hooman Hafezi, Ai Ling Ching, Patricia Johnson, Anuj Patel, Kevin Cheng, Kosuke Iwai